Phosphate Therapeutics is a UK-based independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals. Its lead programme is PT20, a phosphate binder for treating hyperphosphataemia in late-stage renal disease. The company intends to use the capital to complete Phase 2 development of PT20. Phosphate Therapeutics acquired global rights to PT20 from the Medical Research Council. The PT20 programme was initially supported by the MRC’s Development Gap Fund. The company is led by CEO Carl Sterritt. It raised up to €10.5m in funding from Inventages Venture Capital.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2012